ACTIPATCH WILL BECOME A STANDARD OF CARE PRODUCT!
Post# of 8231
(Total Views: 224)
Posted On: 04/12/2025 1:00:33 PM
ACTIPATCH WILL BECOME A STANDARD OF CARE PRODUCT!
With FDA clearance for treatment of knee, back, wrist, hips, ankles, plantar fasciitis and all musculoskeletal pain, how can it not, especially at the low cost of $35 - with a much longer battery life than the competition! The Actipatch FDA clearance allows it to be sold over the counter (without a prescription). The RecoveryRX applications (post operative pain, edema, wound care, etc.) do require a doctor order. Then there is the "wellness" market, as many people use Actipatch for Restless Leg Syndrome (RLS is estimated to affect 10% of adults worldwide), menstrual pain, migraines, etc. Add in RecoveryRx-Veterinary and you have over 10 billion potential repeat customers - every adult and pet on the planet (every month)!
BIEL IS SIMPLE TO ANALYZE!
Q3 2021 was BIEL's only profitable quarter ($22,381) with $414,700 revenue (including $100k+ in covid relief funds). PROFITABILITY IS VERY CLOSE! Seems like $1.5 million annual revenue (or a $400k quarter) should do it, due to BIEL's extremely low operating costs and business model. Then the corresponding pps should hit .01 - and increase .01 for each additional $2.5 million annual revenue (P/E = 100).
BIEL's low cost OEM business model has put the company in position to be profitable soon (if not already). If the upcoming annual report confirms:
1) $800k annual revenue - this will be a significant increase from the the $700k-ish reported the previous two years and get the pps out of the trips;
2) $1.5 million annual revenue (or a $400k quarter) - this will likely achieve cash flow positive/profitability and get the pps to copper.
With FDA clearance for treatment of knee, back, wrist, hips, ankles, plantar fasciitis and all musculoskeletal pain, how can it not, especially at the low cost of $35 - with a much longer battery life than the competition! The Actipatch FDA clearance allows it to be sold over the counter (without a prescription). The RecoveryRX applications (post operative pain, edema, wound care, etc.) do require a doctor order. Then there is the "wellness" market, as many people use Actipatch for Restless Leg Syndrome (RLS is estimated to affect 10% of adults worldwide), menstrual pain, migraines, etc. Add in RecoveryRx-Veterinary and you have over 10 billion potential repeat customers - every adult and pet on the planet (every month)!
BIEL IS SIMPLE TO ANALYZE!
Q3 2021 was BIEL's only profitable quarter ($22,381) with $414,700 revenue (including $100k+ in covid relief funds). PROFITABILITY IS VERY CLOSE! Seems like $1.5 million annual revenue (or a $400k quarter) should do it, due to BIEL's extremely low operating costs and business model. Then the corresponding pps should hit .01 - and increase .01 for each additional $2.5 million annual revenue (P/E = 100).
BIEL's low cost OEM business model has put the company in position to be profitable soon (if not already). If the upcoming annual report confirms:
1) $800k annual revenue - this will be a significant increase from the the $700k-ish reported the previous two years and get the pps out of the trips;
2) $1.5 million annual revenue (or a $400k quarter) - this will likely achieve cash flow positive/profitability and get the pps to copper.
(2)
(0)BioElectronics Corporation (BIEL) Stock Research Links
Scroll down for more posts ▼